Cheryl H. Arrowsmith

Cheryl H. Arrowsmith

SGC Toronto

Arrowsmith

Biography

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.  Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019 and 2022. She was elected an AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

2024

Structure-guided drug discovery: back to the future.

Arrowsmith CH

Nat Struct Mol Biol. 2024-3-15 . 31(3):395-396 .doi: 10.1038/s41594-024-01244-3

PMID: 38486110

Big data and benchmarking initiatives to bridge the gap from AlphaFold to drug design.

Schapira M, Halabelian L, Arrowsmith CH, Harding RJ

Nat Chem Biol. 2024-3-8 . .doi: 10.1038/s41589-024-01570-z

PMID: 38459278

ChemRAP uncovers specific mRNA translation regulation via RNA 5' phospho-methylation.

Ipas H, Gouws EB, Abell NS, Chiou PC, Devanathan SK, Hervé S, Lee S, Mercado M, Reinsborough C, Halabelian L, Arrowsmith CH, Xhemalçe B

EMBO Rep. 2024-1-23 . .doi: 10.1038/s44319-024-00059-z

PMID: 38263329

2023

The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition.

Kimani SW, Perveen S, Szewezyk M, Zeng H, Dong A, Li F, Ghiabi P, Li Y, Chau I, Arrowsmith CH, Barsyte-Lovejoy D, Santhakumar V, Vedadi M, Halabelian L

Commun Biol. 2023-12-16 . 6(1):1272 .doi: 10.1038/s42003-023-05655-8

PMID: 38104184

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.

Alqazzaz MA, Luciani GM, Vu V, Machado RAC, Szewczyk MM, Adamson EC, Cheon S, Li F, Arrowsmith CH, Minden MD, Barsyte-Lovejoy D

Exp Hematol. 2023-12-10 . 104135 .doi: 10.1016/j.exphem.2023.11.009

PMID: 38072134

RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells.

Krishnan R, Lapierre M, Gautreau B, Nixon KCJ, El Ghamrasni S, Patel PS, Hao J, Yerlici VT, Guturi KKN, St-Germain J, Mateo F, Saad A, Algouneh A, Earnshaw R, Shili D, Seitova A, Miller J, Khosraviani N, Penn A, Ho B, Sanchez O, Hande MP, Masson JY, Brown GW, Alaoui-Jamali M, Reynolds JJ, Arrowsmith C, Raught B, Pujana MA, Mekhail K, Stewart GS, Hakem A, Hakem R

Nucleic Acids Res. 2023-9-11 . .doi: 10.1093/nar/gkad733

PMID: 37697435

The RavA-ViaA chaperone complex modulates bacterial persistence through its association with the fumarate reductase enzyme.

Bhandari V, Reichheld SE, Houliston S, Lemak A, Arrowsmith CH, Sharpe S, Houry WA

J Biol Chem. 2023-9-1 . 105199 .doi: 10.1016/j.jbc.2023.105199

PMID: 37660904

The chromatin and single-cell transcriptional landscapes of CD4 T cells in inflammatory bowel disease link risk loci with a proinflammatory Th17 cell population.

Medina TS, Murison A, Smith M, Kinker GS, Chakravarthy A, Vitiello GAF, Turpin W, Shen SY, Yau HL, Sarmento OF, Faubion W, Lupien M, Silverberg MS, Arrowsmith CH, De Carvalho DD

Front Immunol. 2023-8-21 . 14:1161901 .doi: 10.3389/fimmu.2023.1161901

PMID: 37600767

SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.

Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, He HH, Cai C

Proc Natl Acad Sci U S A. 2023-8-15 . 120(33):e2220472120 .doi: 10.1073/pnas.2220472120

PMID: 37549269

SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells.

Uguen M, Deng Y, Li F, Shell DJ, Norris-Drouin JL, Stashko MA, Ackloo S, Arrowsmith CH, James LI, Liu P, Pearce KH, Frye SV

ACS Chem Biol. 2023-8-9 . .doi: 10.1021/acschembio.3c00280

PMID: 37556795